List view / Grid view
Abbott announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test – which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). More than 25 million Americans are…
14 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced the submission of a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate...
14 April 2014 | By Biogen Idec
Biogen Idec will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology Annual Meeting...
11 April 2014 | By The European Medicines Agency
The Pharmacovigilance Risk Assessment Committee gave a recommendation on one safety review and started four new safety reviews at its April meeting...
11 April 2014 | By Merck
Merck announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172...
11 April 2014 | By Daiichi Sankyo
As announced in a release dated April 7, 2014, pursuant to a merger transaction, whereby Daiichi Sankyo Company, Limited has agreed with Sun Pharmaceutical Industries Ltd...
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
10 April 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014...
10 April 2014 | By Abbott
Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold...
9 April 2014 | By The European Medicines Agency
Targeted discussions with key stakeholders in May...
9 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza®...
9 April 2014 | By Johnson & Johnson
Janssen Research & Development, LLC (“Janssen”) today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. This regulatory submission is based on data from the Phase 3 RESONATE™ study in relapsed or…
9 April 2014 | By Novartis
Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014...
8 April 2014 | By OncoEthix
OncoEthix announced that the interim results from its ongoing Phase I clinical trial of OTX015, in patients with hematologic malignancies, were presented at the annual American Association of Cancer Research...
8 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE...
